Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/21/2017 06/22/2017 06/23/2017 06/26/2017 06/27/2017 Date
17.875(c) 17.375(c) 18.125(c) 17.25(c) 17.5 Last
55 000 56 590 11 155 52 335 123 763 Volume
-2.05% -2.80% +4.32% -4.83% +1.45% Change
More quotes
Financials ( GBP)
Sales 2017 16,0 M
EBIT 2017 -32,8 M
Net income 2017 -24,2 M
Finance 2017 15,5 M
Yield 2017 -
Sales 2018 27,8 M
EBIT 2018 -29,5 M
Net income 2018 -33,3 M
Finance 2018 5,93 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 4,69x
EV / Sales2018 3,05x
Capitalization 90,8 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
04/26 VERNALIS : Gets EUR2 Million Milestone Payments From Servier Partnership
04/24 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
04/21 VERNALIS : Cough Cold Treatment Drug Application Suffers Setback
04/21 VERNALIS : *panmure cuts vernalis plc to 'hold' ('buy') - target 65 pence
04/21 VERNALIS : receives a $2 million milestone payment from one of its drug discover..
04/21 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
04/21 VERNALIS PLC : FDA Issues a Complete Response Letter on CCP-07 NDA
03/29 VERNALIS : Block listing Interim Review
03/06 VERNALIS : Partners With Servier On Oncology Drug-Discovery
03/06 VERNALIS : and Servier enter into a new drug discovery collaboration strengtheni..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/22Vernalis plc $VNLPY Upgraded by Zacks Investment Research to “Buy”  
06/21Vernalis plc upgraded by Zacks Investment Research to buy. $0.50 PT.  
06/21Zacks Investment Research Upgrades Vernalis plc $VNLPY to “Buy”  
06/17Vernalis plc downgraded by Zacks Investment Research to hold.  
06/06Vernalis plc upgraded by Zacks Investment Research to hold.  
More tweets
Qtime:5
News from SeekingAlpha
04/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017
04/21 FDA rejects Vernalis' marketing application cough/cold med CCP-07
02/21 Vernalis reports 1H results
2016 Vernalis reports FY16 results
2016 Vernalis ADR reports 6M'15 results
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,58  GBP
Spread / Average Target 239%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-49.26%121
INCYTE CORPORATION34.31%27 907
QUINTILES IMS HOLDINGS..18.58%19 657
LONZA GROUP27.74%16 010
CELLTRION, INC.--.--%12 252
ALKERMES PLC5.20%8 957
More Results